Home

Search Abstracts

Browse Oral Sessions

Browse Poster Sessions

Session 111-Poster Abstracts ART: Randomized Trials Thursday, 2-4 pm; Poster Hall       625 Risk Factors for Mortality among HIV+ Adults Receiving cART in Botswana: Results from a Clinical Trial William Wester*1,2,3, S Eden1, H Bussmann3,4, B Shepherd1, S Moyo4, J Makhema4, V Novitsky3,4, M Essex3,4, and R Marlink3,4 1Vanderbilt Univ Sch of Med, Nashville, TN, US; 2Vanderbilt Inst for Global Hlth, Nashville, TN, US; 3Harvard Sch of Publ Hlth, Boston, MA, US; and 4Botswana-Harvard AIDS Inst Partnership, Gaborone       626 Relationship between Combination of Baseline Viral Load and CD4 Cell Count, and Week 48 or 96 Responses to Rilpivirine or Efavirenz in Treatment-naïve HIV-1+ Adults: Pooled Analysis from the Phase 3 ECHO and THRIVE Trials Calvin Cohen*1, J-M Molina2, D Jayaweera3, J Andrade-Villanueva4, G De La Rosa5, M Stevens6, S Vanveggel6, P Williams6, and K Boven7 1Community Res Initiative of New England, Boston, MA, US; 2Saint Louis Hosp and Univ of Paris, France; 3Univ of Miami, FL, US; 4Hosp Civil de Guadalajara, Mexico; 5Janssen Global Svcs, Titusville, NJ, US; 6Tibotec BVBA, Beerse, Belgium; and 7Tibotec Inc, Titusville, NJ, US       627 Week 48 Results of an Ongoing Global Phase 3 Study Comparing Elvitegravir/Cobicistat/Emtricitabine/Tenofovir (Quad) with Atazanavir/ritonavir plus Emtricitabine/Tenofovir in Treatment-naïve HIV-1+ Subjects Showing Efficacy, Safety, and Pharmacokinetics Edwin DeJesus*1, J Rockstroh2, K Henry3, J-M Molina4, J Gathe5, S Ramanathan6, X Wei6, J Szwarcberg6, A Jandourek6, and A Cheng6 1Orlando Immunology Ctr, FL, US; 2Univ of Bonn, Germany; 3Hennepin County Med Ctr, Minneapolis, MN, US; 4Saint Louis Hosp, Paris, France; 5Therapeutic Concepts PA, Houston, TX, US; and 6Gilead Sci, Foster City, CA, US       628 Comparison of Directly Administered ART vs Self-administered ART in HIV+ Subjects Attending Opioid Treatment Programs: A Randomized Clinical Trial Gregory Lucas*1, B Mullen1, N Galai1, K Oursler2, R Moore1, and K Cook1 1Johns Hopkins Univ, Baltimore, MD, US and 2Univ of Maryland, Baltimore, US       629 MAPS to Improve HIV Treatment Adherence and Virologic Outcomes: A Randomized Controlled Trial Robert Gross*, S Bellamy, J Chapman, X Han, J O’Duor, S Palmer, J Coyne, and B Strom Univ of Pennsylvania, Philadelphia, US       630 Maraviroc as Intensification Strategy in Immunological Non-responder HIV+ Patients with Virologic Success on HAART P Vitiello1, Esther Merlini*2, E Colella1, F Adorni3, F Bai2, M Morosi1, M Galli1, A d’Arminio Monforte2, G Marchetti2, S Rusconi1, and HSL/MVC01/2008 Study Group 1Ospedale Luigi Sacco, Univ di Milan, Italy; 2Clin Malattie Infettive e Tropicali, Univ di Milan, Ospedale San Paolo, Italy; and 3Inst di Tech Biomed, Consiglio Nazionale delle Ricerche, Segrate, Italy       631 Pegylated Interferon-a2A Monotherapy Induces Durable Suppression of HIV-1 Replication and Decreased HIV DNA Integration following ART Interruption L Azzoni1, A Foulkes2, E Papasavvas1, A Mexas3, K Mounzer4, P Tebas5, J Jacobson6, U O’Doherty3, J Kostman5, and Luis Montaner*1 1The Wistar Inst, Philadelphia, PA, US; 2Univ of Massachusetts Sch of Publ Hlth and Hlth Sci, Amherst, US; 3Perelman Sch of Med, Univ of Pennsylvania, Philadelphia, US; 4Jonathan Lax Treatment Ctr, Philadelphia FIGHT, PA, US; 5Univ of Pennsylvania, Philadelphia, US; and 6Drexel Univ, Philadelphia, PA, US